Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure.
Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure.
复制标题
DOI：
10.1038/s41598-021-81517-9
复制
发表时间：
2021-01-21
影响因子：
4.6
通讯作者：
Yamauchi-Takihara K
中科院分区：
文献类型：
--
作者：
Taneike M;Nishida M;Nakanishi K;Sera F;Kioka H;Yamamoto R;Ohtani T;Hikoso S;Moriyama T;Sakata Y;Yamauchi-Takihara K
心力衰竭是老年人死亡的主要原因。一些研究已经证明可溶性α-Klotho（sαKl）参与各种疾病。然而，sαKl和心力衰竭之间的相关性仍有待了解。本研究旨在探讨sαKl在心力衰竭患者中的水平和作用。本研究入组了2010年至2018年在大坂大学医院住院的28例连续急性心力衰竭患者（19例男性，9例女性）。平均NYHA评分、左心室射血分数和BNP分别为3.3、17.0%和588 pg/mL。心力衰竭患者SαKl明显升高。心力衰竭患者经强化治疗后病情好转，入院时SαKl明显高于治疗后病情未好转者。在显示改善的患者中，SαKl水平显著降低。有趣的是，sαKl水平在男性心力衰竭患者中升高，但在女性患者中不升高。我们的数据表明，可溶性αKl可能是射血分数降低的心力衰竭患者治疗反应性的一种新生物标志物。我们的研究结果可能有助于为不同的心力衰竭患者开发个性化治疗。
Heart failure is a major cause of death with an increasing population of elderly individuals. Several studies have demonstrated the involvement of soluble alpha-Klotho (sαKl) in various diseases. However, the correlation between sαKl and heart failure remains to be understood. The aim of this study is to investigate the levels and role of sαKl in patients with heart failure. Twenty-eight consecutive patients with acute heart failure (19 male, 9 female), admitted to the Osaka University Hospital from 2010 to 2018, were enrolled in this study. Mean NYHA score, left ventricular ejection fraction and BNP were 3.3, 17.0% and 588 pg/mL, respectively. SαKl significantly increased in heart failure patients. SαKl on admission were significantly higher in patients with heart failure who showed improvement after intensive treatment than that in patients who did not show improvement after the treatment. SαKl levels decreased significantly in patients who showed improvement. Interestingly, sαKl levels increased in male patients with heart failure, but not in female patients. Our data suggest that soluble αKl may be a novel biomarker for the responsiveness against treatment in patients with heart failure with reduced ejection fraction. Our findings may help developing a personalized therapy for different patients with heart failure.
登录
查看更多内容
影响因子：
3.7
作者：
Kitagawa M;Sugiyama H;Morinaga H;Inoue T;Takiue K;Ogawa A;Yamanari T;Kikumoto Y;Uchida HA;Kitamura S;Maeshima Y;Nakamura K;Ito H;Makino H
通讯作者：
Makino H
影响因子：
4.6
作者：
Nakanishi K;Nishida M;Harada M;Ohama T;Kawada N;Murakami M;Moriyama T;Yamauchi-Takihara K
通讯作者：
Yamauchi-Takihara K
影响因子：
6.3
作者：
Semba RD;Cappola AR;Sun K;Bandinelli S;Dalal M;Crasto C;Guralnik JM;Ferrucci L
通讯作者：
Ferrucci L
影响因子：
20.1
作者：
Mann DL
通讯作者：
Mann DL
影响因子：
16.6
作者：
通讯作者：
--